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Résumé en
anglais
Attention-deficit/hyperactivity disorder (ADHD) is a common and challenging
comorbidity affecting many children with epilepsy. A working group under the
International League Against Epilepsy (ILAE) Pediatric Commission identified key
questions on the identification and management of ADHD in children with epilepsy.
Systematic reviews of the evidence to support approaches to these questions were
collated and graded using criteria from the American Academy of Neurology Practice
Parameter. Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) requirements were followed, with PROSPERO registration
(CRD42018094617). No increased risk of ADHD in boys with epilepsy compared to
girls with epilepsy was found (Level A). Valproate use in pregnancy is associated with
inattentiveness and hyperactivity in offspring (1 class I study), and children with
intellectual and developmental disabilities are at increased risk of ADHD (Level A).
Impact of early seizure onset on development of ADHD was unclear (Level U), but
more evident with poor seizure control (Level B). ADHD screening should be
performed from 6 years of age, or at diagnosis, and repeated annually (Level U) and
reevaluated after change of antiepileptic drug (AED) (Level U). Diagnosis should
involve health practitioners with expert training in ADHD (Level U). Use of the
Strength and Difficulties Questionnaire screening tool is supported (Level B). Formal
cognitive testing is strongly recommended in children with epilepsy who are
struggling at school (Level U). Behavioral problems are more likely with polytherapy
than monotherapy (Level C). Valproate can exacerbate attentional issues in children
with childhood absence epilepsy (Level A). Methylphenidate is tolerated and effective
in children with epilepsy (Level B). Limited evidence supports that atomoxetine is
tolerated (Level C). Multidisciplinary involvement in transition and adult ADHD
clinics is essential (Level U). In conclusion, although recommendations could be
proposed for some of the study questions, this systematic review highlighted the need
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